March 2025. Volume 21. Number 1

Are two doses of the 13-valent pneumococcal vaccine as effective as three doses?

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Bertran M, D'Aeth JC, Abdullahi F, Eletu S, Andrews NJ, Ramsay ME, et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect Dis. 2024;24(5):546-56.

Reviewers: Martínez Rubio M.V1, Albi Rodríguez MS2.
1Pediatra. CS Los Fresnos. Torrejón de Ardoz. Madrid. España.
2Servicio de Pediatría. Hospital Universitario 12 de Octubre. Madrid. España.
Correspondence: M.ª Victoria Martínez Rubio. Email: victmrubio@gmail.com
Reception date: 03/02/2025
Acceptance date: 19/02/2025
Publication date: 26/02/2025

Abstract

Authors´ conclusions: breakthrough and vaccine failure rates were not different between children who received the two-dose pneumococcal conjugate vaccine (PCV13) and the two-dose primary vaccination plus one booster schedule. Overall invasive pneumococcal disease (IPD) incidence was lower in 2022-23, with the two-dose schedule already implanted, than in 2019-20. The post-pandemic increase in childhood IND, after the withdrawal of restrictions, both globally and by PCV13 serotypes (specially 3 serotype), will require close monitoring.

Reviewers´ commentary: although the two-dose schedule of 13-valent pneumococcal vaccine does not appear to increase the risk of infection after vaccination in children under one year of age or vaccination failures in children over one year of age, there are still some doubts about the influence of this schedule change on the incidence of invasive pneumococcal disease that will be appropriate to confirm or rule out in new studies.

How to cite this article

Martínez Rubio MV, Albi Rodríguez MS. ¿Son dos dosis de vacuna 13-valente frente a neumococo tan eficaces como tres dosis? Evid Pediatr. 2025;21:8.

AVC | Critically appraised articles

Bertran M, D'Aeth JC, Abdullahi F, Eletu S, Andrews NJ, Ramsay ME, et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect Dis. 2024;24(5):546-56.

Reviewers: Martínez Rubio M.V1, Albi Rodríguez MS2.
1Pediatra. CS Los Fresnos. Torrejón de Ardoz. Madrid. España.
2Servicio de Pediatría. Hospital Universitario 12 de Octubre. Madrid. España.
Correspondence: M.ª Victoria Martínez Rubio. Email: victmrubio@gmail.com
Reception date: 03/02/2025
Acceptance date: 19/02/2025
Publication date: 26/02/2025

How to cite this article

Martínez Rubio MV, Albi Rodríguez MS. ¿Son dos dosis de vacuna 13-valente frente a neumococo tan eficaces como tres dosis? Evid Pediatr. 2025;21:8.

26/02/2025

Linked Comment